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Overweight/obesity influence disease burden and clinical outcome of Rheumatoid Arthritis (RA). 
The impact of overweight/obesity on synovial tissue (ST) inflammation is largely unknown. Here, we 
investigated the histological and transcriptional signature of ST obtained from RA in different disease 
phases (disease onset, failure to first-line conventional DMARDs and in sustained clinical and ultrasound 
remission) finding that overweight/obese DMARDs naive RA showed higher likelihood of follicular 
synovitis, higher IHC scores for sublining inflammatory cells (CD68+, CD21+ and CD20+) and higher 
IL-1RA plasma levels than normal weight RA. Regardless to the synovitis pattern, overweight/obese 
DMARDs naive RA showed a worse clinical response to “Treat-to-target” (T2T) than normal weight RA 
at 6 and 12 months follow-up. Conversely, MTX-IR RA did not show significant differences in synovial 
inflammation based on BMI category. Overweight/obese RA in stable clinical and US remission showed 
higher degree of residual synovitis in terms of sublining CD68+, CD20+ cells and lining and sublining 
CD3+ compared to normal weight RA. Finally, gene expression profile analysis revealed that ST of 
overweight/obese DMARDs naive RA is enriched by CCL3 and MyD88 compared to normal weight 
RA in sustained disease remission, the latter correlating with BMI and IHC scores for synovial CD68+ 
cells. These findings suggest that indeed overweight/obese RA show higher degree of synovitis at 
disease onset and after remission achievement that influences the response rate to T2T and should be 
considered within the management of patients with RA.
There are increasing evidences that overweight and obesity are risk factors for the development of Rheumatoid 
Arthritis (RA) and that a high Body Mass Index (BMI) is associated with high disease activity and disability at 
disease onset1–3, being an independent factor of worse clinical response to RA treatment4–6. Despite this, pooling 
data derived from multiple imaging studies showed that BMI is inversely associated with joint inflammation 
compared to normal weight RA7–9.
A recent study on animal models of arthritis confirmed that the effect of obesity on synovial tissue (ST) 
inflammation is contingent on the disease phase being more significant at disease onset and in the resolution 
phase10, as promoted by the aberrant release of pro-inflammatory cytokines from adipocytes in obese arthritic 
animals which enhance the persistence of pro-inflammatory cells within the ST delaying the inflammatory pro-
cess resolution. Despite this, it has to be mentioned that obese RA were found to be protected by bone damage11,12. 
To date, no information is available on ST analysis of such population in humans, with a lack of knowledge about 
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the molecular mechanisms associated with synovial inflammation in overweight/obese RA, in different disease 
phases, regulating tissue inflammation and bone protection.
Based on this, the aims of the present study were: (i) to define the histological features of RA ST in differ-
ent disease phases (disease onset or first conventional DMARD failure) in terms of CD68+, CD21+, CD3+ and 
CD20+ cells ST distribution based on the BMI category; (ii) to dissect if overweight/obesity status is associated 
with the aberrant expression of cytokines related to inflammation [i.e. Interleukin-6 (IL-6)] and bone damage [i.e. 
Interleukin-1 Receptor Antagonist (IL-1RA)] in naive to treatment RA; (iii) to define if BMI category, associated 
with ST characteristics, may influence the response rate to a treat to target strategy in naive to treatment RA and 
(iv) to dissect weather the BMI category may affect the histological features of residual synovitis in RA in stable 
clinical and ultrasound remission.
Results
Demographic, clinical and immunological characteristics of the study cohorts. Table 1 summa-
rizes the demographic, clinical and immunological characteristics of the study cohorts. In particular, naive to 
treatment RA were significantly younger than MTX-IR RA (p = 0.03) and RA in stable clinical and ultrasound 
remission (p = 0.04). Naive to treatment RA had similar disease activity than MTX-IR RA (3.7 ± 1.3 vs 3.3 ± 1.1; 
p = 0.10) and significantly higher than RA in stable clinical and ultrasound remission (1.0 ± 0.4; p < 0.001). 
Considering the BMI categories, the overweight/obesity rate was comparable among the three study cohorts 
(60.0% naive RA had BMI ≥ 25 kg/m2 compared to 58.1% MTX-IR RA and 60.0% RA in sustained clinical and 
ultrasound remission; p > 0.05). Considering the autoimmune profile, there was no significant difference in terms 
of autoantibody positivity in the three study cohorts based on the BMI category (p = 0.52, p = 0.48 and p = 0.61 
comparing autoantibody positivity based on BMI category within the naive to treatment RA, MTX-IR RA and 
RA in sustained remission cohorts respectively). Considering the bone damage, the percentage of erosive naive 
RA at disease onset was 37.1% with no significant difference stratifying according to the BMI category (28.6% in 
RA patients with BMI < 25 kg/m2 and 42.9% in patients with BMI ≥ 25 kg/m2 respectively; p = 0.17). Moreover, 
demographic, clinical and immunological characteristics of the study cohorts stratified based on BMI category 
are summarized in Supplementary Table 1.
BMI influences IHC characteristics of RA at disease onset in terms of synovial resident inflam-
matory cells. Among naive to treatment RA, subjects with BMI ≥ 25 Kg/m2 showed a higher rate of synovial 
inflammation compared to normal weight RA (Fig. 1A–H). In particular, naïve RA with BMI ≥ 25 Kg/m2 had 
more likely follicular synovitis pattern (71.4%) than normal weight naïve RA (39.3%; p = 0.001) (Fig. 1I). Double 
immunohistochemistry showed that naïve RA with BMI ≥ 25 Kg/m2 showed significantly higher IHC score for 
sublining CD68+ (2.1 ± 0.8) (Fig. 1J), CD21+ (1.0 ± 1.1) (Fig. 1K) and CD20+ cells (1.9 ± 0.9) (Fig. 1L) compared 
to normal weight RA (1.5 ± 0.9 for CD68+ cells; p = 0.01; 0.5 ± 0.8 for CD21+ cells; p = 0.03; and 1.4 ± 0.8 for 
CD20+ cells; p = 0.05, respectively). Moreover, considering the whole cohort of naive RA, BMI value directly 
correlated with the IHC scores for lining CD68+ (R = 0.24; p = 0.04), lining CD21+ (R = 0.36; p = 0.002) and sub-
lining CD68+ (R = 0.39; p = 0.001) (Fig. 1N), sublining CD21+ (R = 0.37; p = 0.002), sublining CD20+ (R = 0.38; 
p = 0.001) and sublining CD3+ cells (R = 0.33; p = 0.005) respectively (Fig. 1O) and with the synovial aggregate 
grade (R = 0.33; p = 0.005) (Fig. 1P).
Naive RA 
(n = 70)
MTX-IR RA 
(n = 43)
Remission RA 
(n = 25) pa pb pc
Female, n(%) 55 (78.6) 39 (90.7) 21 (84.0) 0.10 0.39 0.40
Age, years (mean ± SD) 53.5 ± 15.4 59.5 ± 13.8 57.2 ± 14.9 0.03 0.04 0.65
Disease duration, years (mean ± SD) 1.9 ± 0.7 6.1 ± 4.6 9.7 ± 2.8 <0.001 <0.001 0.01
AB positivity, n(%) 36 (51.4) 25 (58.1) 17 (68.0) 0.48 0.11 0.42
DAS, (mean ± SD) 3.7 ± 1.3 3.3 ± 1.1 1.1 ± 0.4 0.10 <0.001 <0.001
BMI ≥ 25 Kg/m2, n(%) 42 (60.0) 25 (58.1) 15 (60.0) 0.54 0.59 0.00
BMI, (mean ± SD) 27.2 ± 5.8 26.7 ± 5.3 25.8 ± 4.1 0.64 0.44 0.34
ESR, mm/1st hour (mean ± SD) 53.3 ± 30.5 48.4 ± 32.6 17.0 ± 16.1 0.43 <0.001 <0.001
CRP, mg/L (mean ± SD) 22.1 ± 22.1 18.4 ± 22.2 2.1 ± 2.0 0.27 <0.001 <0.001
Treatment regimen
MTX dose, mg/week — 13.8 ± 5.7 14.4 ± 3.6 — — 0.64
Etanercept 50 mg/week — — 13 (52.0) — — —
Adalimumab 40 mg/2 weeks — — 12 (48.0) — — —
Table 1. Demographic, clinical and immunological characteristics of the study cohorts. AB: autoantibody; 
BMI: Body Mass Index; CRP: C Reactive Protein; DAS: Disease Activity Score; ESR: Erythrocyte Sedimentation 
Rate; RA: Rheumatoid Arthritis. MTX-IR: Methotrexate inadequate responder; pa: naïve RA vs MTX-IR 
RA patients; pb: naïve RA vs remission RA patients; pc: MTX-IR RA vs remission RA patients; SD: Standard 
Deviation; Bold: p < 0.05.
3Scientific RepoRts |         (2019) 9:10420  | https://doi.org/10.1038/s41598-019-46927-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 1. (A–P) Legend: IHC staining for CD68/CD21 and CD3/CD20 on ST of naive to DMARDs treatment 
Rheumatoid Arthritis patients based on the BMI category. (A,B) Example photos of CD68(red)/CD21(brown) 
staining of ST biopsies from naive to DMARDs RA with BMI < 25 kg/m2; (C,D) Example photos of CD3(red)/
CD20(brown) staining of ST biopsies from naive to DMARDs RA with BMI < 25 kg/m2; (E,F) Example photos 
of CD68(red)/CD21(brown) staining of ST biopsies from naive to DMARDs RA with BMI ≥ 25 kg/m2; (G,H) 
Example photos of CD3(red)/CD20(brown) staining of ST biopsies from naive to DMARDs RA patients with 
BMI ≥ 25 kg/m2 (all magnifications 20X); (I) Rate of follicular synovitis in naive to DMARDs RA at disease 
onset with BMI < 25Kg/m2 (39.3%) vs RA with BMI ≥ 25 kg/m2 (71.4%, *p = 0.001); (J) Lining and sublining 
IHC score for CD68 cells in ST of naive to DMARDs RA based on BMI category; Lining and sublining CD68 
IHC score of overweight/obese vs normal weight naive to DMARDs RA (p = 0.21 and *p = 0.01 respectively); 
(K) Lining and sublining IHC score for CD21 cells in ST of naive to DMARDs RA based on BMI category; 
Lining and sublining CD21 IHC score of overweight/obese vs normal weight naive to DMARDs RA (p = 0.06 
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Overweight/obese RA patients at disease onset show aberrant levels of inflammatory 
cytokines associated to the degree of synovial inflammation. To assess if overweight/obe-
sity status might be related to aberrant systemic inflammation, levels of inflammatory (i.e. IL-6) and 
anti-inflammatory (i.e. IL-1RA) cytokines were assessed in PB of naive RA and in RA patients in stable clinical 
and ultrasound remission at the time of ST biopsy. Plasma levels of IL-6 were significantly higher at RA onset 
(48.4 ± 56.5 pg/ml) than in RA in sustained remission (3.4 ± 7.9 pg/ml; p < 0.001), whereas IL-1RA plasma 
levels were not statistically different between naïve RA (647.3 ± 397.9 pg/ml) and RA in sustained remission 
(464.4 ± 217.4 pg/ml; p = 0.07).
Considering naive RA based on the BMI category, patients with BMI ≥ 25 Kg/m2 showed significantly 
higher IL-1RA plasma levels (766.5 ± 431.1 pg/ml) that patients with BMI < 25 Kg/m2 (465.9 ± 257.0; p = 0.002) 
(Fig. 2A). Moreover, stratifying naive RA according to the synovitis pattern, patients with BMI ≥ 25 Kg/m2 showed 
higher IL-1RA plasma levels regardless to the presence of diffuse (728.5 ± 410.5 pg/ml) or follicular pattern 
(784.2 ± 457.8 pg/ml) compared to patients with BMI < 25 kg/m2 (485.6 ± 302.9 pg/ml in RA patients with diffuse 
synovitis; p = 0.05; 469.3 ± 197.4 pg/ml in RA patients with follicular synovitis; p = 0.04) (Fig. 2B). Moreover, in 
naive RA IL-1RA plasma levels directly correlated with DAS (R = 0.35; p = 0.01) and BMI (R = 0.35; p = 0.01) 
suggesting a tight link between disease activity and burden of inflammation as well as fat tissue excess at RA onset 
(Fig. 2C,D). Considering the presence of bone damage, erosive naive RA showed higher IL-6 (66.6 ± 56.9 pg/ml) 
and IL-1RA plasma levels (789.5 ± 412.0 pg/ml) than no erosive patients (IL-6: 38.4 ± 54.3 pg/ml; p = 0.05 and 
IL-1RA: 571.1 ± 374.1 pg/ml; p = 0.04). Conversely, RA in sustained remission without erosive disease showed 
higher IL-1RA plasma levels (577.0 ± 221.0 pg/ml) than no erosive ones (316.9 ± 88.9 pg/ml; p = 0.002) (see 
Supplementary Fig. 1A,B), directly related to BMI value (see Supplementary Table 2). As a consequence, consid-
ering the presence of erosions based on BMI category, the lowest plasma IL-6/IL-1RA ratio was found in over-
weight/obese naive RA without erosive disease than in normal weight naive RA with or without erosive disease 
and overweight/obese naive RA with erosive disease (p = 0.01 for all comparisons) (see Supplementary Fig. 1C).
Considering the pooled cohorts of naive RA and RA in remission, IL-6 plasma levels directly correlated with the 
IHC scores for lining CD68+ (R = 0.47; p < 0.001), lining CD3+ (R = 0.34; p = 0.002) and lining CD20+ (R = 0.35; 
p = 0.002) cells (Fig. 2E) and with the IHC scores for sublining CD68+ (R = 0.46; p < 0.001), sublining CD21+ 
(R = 0.36; p = 0.001), sublining CD3+ (R = 0.39; p < 0.001) and sublining CD20+ (R = 0.37; p = 0.001) cells (Fig. 2F).
BMI category influences the response rate to T2T strategy in naive to treatment RA inde-
pendently from synovitis pattern. The analysis of overweight/obesity status effect on remission achieve-
ment after T2T scheme, revealed that naive RA with BMI ≥ 25 kg/m2 showed significantly lower rate of DAS 
remission after 6 months (28.2%) and 12 months (37.8%) follow-up compared to naive RA with BMI < 25 kg/m2 
(57.1% and 67.9% RA in DAS remission after 6 and 12 months of follow-up; p = 0.02 and p = 0.01 respectively). 
Stratifying naive RA based on the synovitis pattern detected at the ST level, before the beginning of DMARDs 
treatment, RA with BMI ≥ 25 kg/m2 and follicular synovitis showed significantly lower rate of DAS remission 
achievement after 6 (34.5%) and 12 months (37.8%) follow-up compared to RA with BMI < 25 kg/m2 and diffuse 
synovitis [64.7% and 70.6% RA with BMI < 25 kg/m2 and diffuse synovitis in DAS remission after 6 (p = 0.005) 
and 12 months (p = 0.03) follow-up] treated with the T2T (see Supplementary Fig. 2A,B). Moreover, considering 
the IHC scores for inflammatory synovial cells, there were no significant differences in terms of baseline IHC 
scores for CD68+, CD21+, CD20+ and CD3+ cells comparing RA reaching or not DAS remission after 6 and 12 
months follow-up, regardless to the BMI category (data not shown). None of the naive RA experienced significant 
weight variation leading to change of the initial BMI category during the follow-up.
BMI does not influence IHC characteristics of RA patients inadequately responding to MTX. 
Since overweight/obesity status affected the response rate to T2T strategy (see Supplementary Fig. 2A,B), we 
analysed histological synovial features of an independent cohort of MTX-IR RA, finding no significant differ-
ence in terms of ST inflammation stratifying patients based on the BMI category (Fig. 3A–H). In particular, in 
MTX-IR RA there was a similar rate of follicular synovitis comparing patients with BMI ≥ 25 kg/m2 (48.2%) and 
patients with BMI < 25 kg/m2 (52.1%; p = 0.83) (Fig. 3I). Moreover, there were no significant differences in lining 
and sublining IHC scores for CD68+, CD21+, CD3+ and CD20+ cells in MTX-IR RA based on the BMI category 
(Fig. 3J,M). Therefore, the inflammation driving the MTX-IR seems to reside in the joint not in the fat tissue.
BMI influences IHC characteristics of synovial tissue residual inflammation of RA patients in stable 
clinical and ultrasound remission in terms of synovial resident inflammatory cells. Among RA in 
stable clinical and US remission under MTX + TNF-i, patients with BMI ≥ 25 kg/m2, showed higher rate of residual 
and *p = 0.03 respectively); (L) Lining and sublining IHC score for CD20 cells in ST of naive to DMARDs RA 
based on BMI category; Lining and sublining CD20 IHC score of overweight/obese vs normal weight naive to 
DMARDs RA (p = 0.71 and *p = 0.05 respectively); (M) Lining and sublining IHC score for CD3 cells in ST 
of naive to DMARDs RA based on BMI category; Lining and sublining CD3 IHC score of overweight/obese vs 
normal weight naive to DMARDs RA patients (p = 0.79 and p = 0.17 respectively); (N) Correlations between 
lining and sublining IHC scores for CD68+ cells and BMI in naive to DMARDs RA patients; (O) Correlations 
between sublining IHC score of CD21+, CD20+ and CD3+ cells and BMI in naive to DMARDs RA patients; (P) 
Correlations between synovial aggregate grade value and BMI (R = 0.33; p = 0.005) in naïve to DMARDs RA; 
RA: Rheumatoid Arthritis; DMARDs: Disease Modifying Anti-Rheumatic Drugs; BMI: Body Mass Index; ST: 
Synovial Tissue; IHC: Immunohistochemistry; CD: Cluster Designation.
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synovial inflammation compared to RA with BMI < 25 kg/m2 (Fig. 4A–H). In particular, RA in stable clinical and US 
remission with BMI ≥ 25 kg/m2 showed significantly higher IHC score for sublining CD68+ (1.2 ± 0.3) (Fig. 4I), lining 
CD20+ cells (0.6 ± 0.4) (Fig. 4J), lining CD3+ (0.6 ± 0.5) and sublining CD3+ (1.1 ± 0.4) cells (Fig. 4K) compared to 
RA with BMI < 25 kg/m2 (0.2 ± 0.4 for sublining CD68+ cells; p < 0.001; 0.2 ± 0.4 for lining CD20+ cells; p = 0.02; 
0.1 ± 0.3 for lining CD3+ cells, p = 0.02; and 0.9 ± 0.3 for sublining CD3+ cells; p = 0.04 respectively). In addition, con-
sidering the whole cohort of RA in stable clinical and US remission, BMI value directly correlated with the IHC scores 
for sublining CD68+ (R = 0.39; p = 0.001) whereas no correlations were found between BMI and sublining CD3+ 
(R = 0.30; p = 0.14) and CD20+ cells (R = 0.10; p = 0.63) (Fig. 4L). Finally, IL-6 plasma levels directly correlated with 
the IHC score of sublining CD68+ cells in ST of RA in stable clinical and ultrasound remission (R = 0.43; p = 0.04) 
with a higher significance considering RA in sustained remission with BMI ≥ 25 kg/m2 (R = 0.66; p = 0.01) (Fig. 4M).
BMI influences transcriptional signature of synovial tissue of RA patients at disease onset and 
at the time of sustained remission achievement. Gene expression profile assay (Fig. 5A) revealed that 
among naive to treatment RA, subjects with BMI ≥ 25 Kg/m2 showed significant over-expression of CCL3 (5.23 
fold; p = 0.02), CCR1 (2.07 fold; p = 0.03), CCR2 (2.90 fold; p = 0.02), FAS-L (5.77 fold; p = 0.03) and MyD88 
(4.33 fold; p = 0.02) compared to RA patients in sustained clinical and ultrasound remission with BMI < 25 Kg/
m2 (Fig. 5B–G). Interestingly, despite comparable disease control, RA patients in sustained clinical and ultrasound 
Figure 2. (A–F) Legend: Association between cytokines plasma levels, BMI and degree of synovial 
inflammation in naïve RA patients and in RA patients in stable clinical and ultrasound remission. (A) IL-1RA 
plasma levels in naïve to treatment RA patients based on the BMI category, *p = 0.002; (B) IL-1RA plasma 
levels in naïve to treatment RA based on the BMI category and synovitis pattern, *p = 0.05 and **p = 0.04; (C) 
Correlation between IL-1RA plasma levels and BMI value in naïve to treatment RA patients; (D) Correlation 
between IL-1RA plasma levels and DAS value in naïve to treatment RA patients; (E) Correlations between 
IL-6 plasma levels and lining IHC scores for CD68+, CD3+ and CD20+ cells in naïve to treatment RA patients 
and RA patients in stable clinical and ultrasound remission; (F) Correlations between IL-6 plasma levels 
and sublining IHC scores for CD68+, CD21+, CD3+ and CD20+ cells in naïve to treatment RA patients and 
RA in stable clinical and ultrasound remission; RA: Rheumatoid Arthritis; BMI: Body Mass Index; IHC: 
Immunohistochemistry; CD: Cluster Designation.
6Scientific RepoRts |         (2019) 9:10420  | https://doi.org/10.1038/s41598-019-46927-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. (A–M) Legend: IHC staining for CD68/CD21 and CD3/CD20 on ST of patients with Rheumatoid 
Arthritis inadequately responder to MTX based on the BMI category. (A,B) Example photos of CD68(red)/
CD21(brown) staining of ST biopsies from MTX-IR RA with BMI < 25 kg/m2; (C,D) Example photos of 
CD3(red)/CD20(brown) staining of ST biopsies from MTX-IR RA with BMI < 25 kg/m2; (E,F) Example photos 
of CD68(red)/CD21(brown) staining of ST biopsies from MTX-IR RA with BMI ≥ 25 kg/m2; (G,H) Example 
photos of CD3(red)/CD20(brown) staining of ST biopsies from MTX-IR RA patients with BMI ≥ 25 kg/m2;  
(all magnifications 20X) (I) Rate of follicular synovitis in MTX-IR RA with BMI < 25 Kg/m2 (50.0%) vs 
MTX-IR RA with BMI ≥ 25 Kg/m2 (48.0%; p = 0.97); (J) Lining and sublining IHC score for CD68 cells in ST 
of MTX-IR RA based on BMI category; Lining and sublining CD68 IHC score of overweight/obese vs normal 
weight MTX-IR RA (p = 0.95 and p = 0.90 respectively); (K) Lining and sublining IHC score for CD21 cells 
in ST of MTX-IR RA based on BMI category; Lining and sublining CD21 IHC score of overweight/obese vs 
normal weight MTX-IR RA (p = 0.89 and p = 0.79 respectively); (L) Lining and sublining IHC score for CD20 
cells in ST of MTX-IR RA based on BMI category; Lining and sublining CD20 IHC score of overweight/obese 
vs normal weight MTX-IR RA (p = 0.92 and p = 0.38 respectively); (M) Lining and sublining IHC score for 
CD3 cells in ST of MTX-IR RA based on BMI category; Lining and sublining CD3 IHC score of overweight/
obese vs normal weight MTX-IR RA (p = 0.80 and p = 0.49 respectively); RA: Rheumatoid Arthritis; MTX-IR: 
inadequately responder to Methotrexate; ST: Synovial Tissue; IHC: Immunohistochemistry; BMI: Body Mass 
Index; CD: Cluster Designation.
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Figure 4. (A–L) Legend: IHC staining for CD68/CD21 and CD3/CD20 on ST of patients with Rheumatoid 
Arthritis in clinical and ultrasound remission under MTX + TNF-i based on the BMI category. (A,B) Example 
photos of CD68(red)/CD21(brown) staining of ST from RA with BMI < 25 kg/m2 in clinical and ultrasound 
remission under MTX + TNF-i; (C,D) Example photos of CD3(red)/CD20(brown) staining of ST from RA 
with BMI < 25 kg/m2 in clinical and ultrasound remission under MTX + TNF-i; (E,F) Example photos of 
CD68(red)/CD21(brown) staining of ST from RA with BMI ≥ 25 kg/m2 in clinical and ultrasound remission 
under MTX + TNF-i; (G,H) Example photos of CD3(red)/CD20(brown) staining of ST from RA with 
BMI ≥ 25 kg/m2 in clinical and ultrasound remission under MTX + TNF-i (all magnifications 20X); (I) Lining 
and sublining IHC score for CD68 cells in ST of RA in clinical and ultrasound remission under MTX + TNF-i 
based on BMI category; Lining and sublining CD68 IHC score of overweight/obese vs normal weight RA in 
clinical and ultrasound remission under MTX + TNF-i (p = 0.17 and *p < 0.001 respectively); (J) Lining and 
sublining IHC score for CD20 cells in ST of RA in clinical and ultrasound remission under MTX + TNF-i 
based on BMI category; Lining and sublining CD20 IHC score of overweight/obese vs normal weight RA in 
clinical and ultrasound remission under MTX + TNF-i (p = 0.95 and *p = 0.02 respectively); (K) Lining and 
sublining IHC score for CD3 cells in ST of RA in clinical and ultrasound remission under MTX + TNF-i based 
on BMI category; Lining and sublining CD3 IHC score of overweight/obese vs normal weight RA in clinical 
and ultrasound remission under MTX + TNF-i (*p = 0.02 and *p = 0.04 respectively); (L) Correlations between 
IHC scores of sublining CD68+, CD20+ and CD3+ cells and BMI (R = 0.39, p = 0.001 for CD68+, R = 0.10, 
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remission with BMI ≥ 25 Kg/m2 showed significant over-expression of MyD88 (2.49 fold; p = 0.04) compared to 
RA patients in sustained clinical and ultrasound remission with BMI < 25 Kg/m2 (Fig. 5G). Considering the 
whole RA cohort used for gene expression profile experiment, synovial tissue expression of MyD88 directly corre-
lates with BMI value (R = 0.58, p = 0.02) and IHC scores for lining and sublining CD68+ cells (R = 0.59, p = 0.02 
and R = 0.56, p = 0.03 for lining and sublining CD68+ cells respectively) in RA patients (Fig. 5H,I).
Discussion
This study shows that overweight/obesity affects the histological features and the gene expression profile of ST 
of RA patients at the time of disease onset and at achievement of sustained clinical and ultrasound remission. In 
addition, overweight/obesity condition at the time of DMARDs beginning influences the rate of disease remission 
achievement in RA treated according to the T2T strategy regardless to the synovitis pattern found at ST level at 
disease onset.
RA is a chronic disease in which inflammatory cells aberrantly migrate within the ST contributing to joint 
inflammation and bone damage13,14. Obesity incidence is increasing in the general population15, and multiple 
studies confirmed that obesity is a risk factor associated with RA development16–18. Several lines of evidence have 
proven that adipose tissue is an endocrine organ acting not only on metabolism but even on immune and inflam-
matory processes by releasing inflammatory molecules promoting the chronicity of the inflammatory response 
in the target tissue19. It has been shown that the overweight/obesity status is associated with a higher degree of 
systemic inflammation and disease burden in RA patients at disease onset3,20, and with an inferior response to 
treatment1,6,21–23. Adipose tissue in normal weight subjects is mostly composed by mature adipocytes, their pre-
cursors, fibroblasts, endothelial cells and scarce immune cells, mainly macrophages24. During the progressive and 
excessive fat accumulation occurring in overweight/obese subjects, there is a substantial increase in the number 
of immune cells and a change in their phenotype towards pro-inflammatory cells contributing to the development 
of obesity-related local and systemic inflammation (the so called low grade inflammation)25. In particular, within 
the adipose tissue of obese individuals, macrophages are the most abundant resident immune cells characterized 
by a pro-inflammatory (M1) phenotype, active in the secretion of inflammatory cytokines10,26. In the present 
study, for the first time, we evaluated the histological features of ST of RA patients enrolled at different disease 
phases (i.e. naive to treatment, inadequately responder to conventional DMARDs and at the time of stable clinical 
and US remission after MTX + TNF-i combined therapy) stratified according to the BMI category. Considering 
RA at onset, before any DMARDs treatment, we found that overweight/obese RA showed higher rate of follicular 
synovitis and higher IHC scores for resident synovial inflammatory cells (i.e. CD68+, CD21+ and CD20+) com-
pared to normal weight ones, with a direct correlation between BMI value and IHC scores for resident inflamma-
tory cells suggesting a tight link between body weight and degree of ST inflammation at RA onset. These findings 
are in line with Kim et al.’s study which investigated the early effect of obesity in RA using preclinical animal 
models, finding that obese Collagen Induced Arthritis (CIA) mice have an earlier disease onset compared to the 
lean ones due to a faster immune cells migration within the joint tissue10.
To date, despite the direct association between high BMI and disease activity in RA, bone damage is less likely 
associated with obesity in RA11,12, suggesting that protective factors may be present in obese patients. It’s well 
known that adipose tissue is a major source of IL-1RA27, whose release was found to be increased in human obe-
sity28. In our cohort, we found that naive overweight/obese RA showed higher IL-1RA plasma levels compared 
to normal weight RA regardless to the synovitis subtype directly related to IL-6 plasma levels possibly due to 
the inflammatory status. Moreover, despite we observed no differences at baseline in erosion score comparing 
overweight/obese and normal weight naïve to treatment RA patients, overweight/obese naive RA without erosive 
disease showed the lowest IL-6/IL-1RA ratio supporting the concept of an unbalance between pro-inflammatory 
and osteoclastogenic via OPG/RANK pathway, such as IL-629, and bone protective (as IL-1RA) soluble factors 
in naive RA based on BMI category. Interestingly, at the time of sustained remission achievement, IL-1RA is sig-
nificantly higher in overweight/obese RA who did not developed erosive disease, supporting the hypothesis that 
overweight/obese RA patients may have been protected through IL-1RA pathway from bone damage.
Finally, to investigate the role of overweight/obesity status on ST composition during the remission phase 
of the disease, we included in the study RA patients in stable sustained clinical and ultrasound remission under 
combination therapy with MTX + TNF-i as previously described30. We found that overweight/obese RA patients 
reaching stable clinical and ultrasound remission showed higher degree of residual synovitis in terms of synovial 
CD68+, CD20+ and CD3+ cells whose IHC scores directly correlated with the BMI value at the time of remission 
achievement. Interestingly, IL-6 plasma levels, despite significantly reduced at the time of remission achieve-
ment compared to patients at diagnosis, directly correlates with the IHC score for sublining CD68+ cells only in 
overweight/obese RA in sustained clinical and ultrasound remission, supporting the notion that fat excess can 
promote IL-6 release, contributing to the persistence of residual synovial inflammation, despite good clinical 
response. These findings are in line with previous data from animal models showing that obese arthritic mice 
show a significant delay in remission achievement compared to lean ones due to the aberrant polarization, within 
the synovial tissue, of macrophages towards a pro-inflammatory (M1) phenotype10.
p = 0.63 for CD20+ and R = 0.30, p = 0.14 for CD3+ cells respectively) in RA in stable clinical and ultrasound 
remission under MTX + TNF-i; (M) Correlation between IL-6 PB levels and IHC of sublining CD68+ cells 
(R = 0.43; p = 0.04) in RA in stable clinical and ultrasound remission under MTX + TNF-i (red dots indicate 
RA with BMI ≥ 25 kg/m2 and green dots indicate RA with BMI < 25 kg/m2, respectively); RA: Rheumatoid 
Arthritis; IHC: Immunohistochemistry; BMI: Body Mass Index; CD: Cluster designation; MTX: Methotrexate; 
TNF-i: Tumor Necrosis factor inhibitor.
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These concepts are strengthened by the findings obtained from the gene expression analysis conducted, in 
the exploratory cohort, on ST from RA at different disease phases stratified by BMI category, revealing that ST 
from naive overweight/obese RA is enriched by inflammatory genes as CCL3 and MyD88 compared to nor-
mal weight RA in sustained disease remission. Interestingly, ST biopsies from overweight/obese RA in sustained 
remission showed a persistent over-expression of MyD88 compared to normal weight RA in sustained disease 
remission. MyD88 (myeloid differentiation primary response gene 88) is a central adaptor molecule for the 
majority of Toll-like receptors (TLRs), which are the most studied pathogen recognition receptors31,32. TLR are 
Figure 5. (A–I) Legend: Gene expression profile of synovial tissue of RA patients with naive to treatment active 
disease and in sustained clinical and ultrasound remission based on BMI category. (A) Clustergram of the dataset 
displaying a heat map indicating expression of genes across individual samples (naive to treatment active RA 
and RA in sustained clinical and ultrasound remission based on BMI category); (B) CCL3 expression in naive 
to treatment active RA and RA in sustained clinical and ultrasound remission based on BMI category; *p = 0.02 
CCL3 gene expression in synovial tissue of naive to treatment active RA with BMI ≥ 25 Kg/m2 compared to RA 
patients in sustained clinical and ultrasound remission with BMI < 25 Kg/m2; (C) CCR1 expression in naive to 
treatment active RA and RA in sustained clinical and ultrasound remission based on BMI category; *p = 0.03 
CCR1 gene expression in synovial tissue of naive to treatment active RA with BMI ≥ 25 Kg/m2 compared to RA 
patients in sustained clinical and ultrasound remission with BMI < 25 Kg/m2; (D) CCR2 expression in naive to 
treatment active RA and RA in sustained clinical and ultrasound remission based on BMI category; *p = 0.02 
CCR2 gene expression in synovial tissue of naive to treatment active RA with BMI ≥ 25 Kg/m2 and **p = 0.001 
CCR2 in RA patients in sustained clinical and ultrasound remission BMI ≥ 25 Kg/m2 compared to RA patients 
in sustained clinical and ultrasound remission with BMI < 25 Kg/m2; (E) FAS-L expression in naive to treatment 
active RA and RA in sustained clinical and ultrasound remission based on BMI category; *p = 0.03 FAS-L gene 
expression in synovial tissue of naive to treatment active RA with BMI ≥ 25 Kg/m2 compared to RA patients in 
sustained clinical and ultrasound remission with BMI < 25 Kg/m2; (F) IL1R1 expression in naive to treatment 
active RA and RA in sustained clinical and ultrasound remission based on BMI category; *p = 0.02 IL1R1 gene 
expression in synovial tissue of naive to treatment active RA with BMI < 25 Kg/m2 compared to RA patients in 
sustained clinical and ultrasound remission with BMI < 25 Kg/m2; (G) MyD88 expression in naive to treatment 
active RA and RA in sustained clinical and ultrasound remission based on BMI category; *p = 0.02 MyD88 gene 
expression in synovial tissue of naive to treatment active RA with BMI ≥ 25 Kg/m2 and **p = 0.04 MyD88 gene 
expression in synovial tissue of RA in sustained remission with BMI ≥ 25 Kg/m2 compared to RA patients in 
sustained clinical and ultrasound remission with BMI < 25 Kg/m2; (H) Correlations between MyD88 expression 
in synovial tissue of RA patients and IHC scores for lining (R = 0.59; p = 0.02) and sublining (R = 0.56; p = 0.03) 
CD68+ cells; (I) Correlations between MyD88 expression in synovial tissue of RA patients and BMI value 
(R = 0.58; p = 0.02); IHC: Immunohistochemistry; CD: Cluster designation. RA: Rheumatoid Arthritis; BMI: 
Body Mass Index.
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trans-membrane receptors that play a crucial role in pathogen recognition and immune response by activating 
various inflammatory signaling pathways, including MyD88, which then leads to an activation of NF-kB signal-
ing activity32. High fat diet was demonstrated to induce an increased expression of TLR in murine adipose tissue 
causing the activation of MyD88 signaling cascades33, and MyD88 expression was found to be increased in both 
peripheral blood mononuclear cells and subcutaneous adipose tissue of overweight/obese subjects compared 
to normal weight controls34. Moreover, MyD88 deficient mice are partially protected to high fat diet induced 
obesity35. Yu et al. demonstrated that MyD88 signaling in myeloid cells participates in the initiation and progres-
sion of obesity-induced systemic low grade inflammation since MyD88 deficiency in myeloid cells inhibits mac-
rophage recruitment to adipose tissue and their switch to an M1-like phenotype36. These findings are in line with 
MyD88 expression in ST of RA patients, directly correlating with BMI value regardless to RA phase and with the 
IHC scores of lining and sublining CD68+ cells in ST biopsies supporting the notion that an aberrant persistent 
over-expression of MyD88, dependent from fat mass excess, is involved in the promotion of residual synovitis 
persistence in ST of overweight/obese RA, despite sustained disease control.
Therefore, based on our findings we conclude that the early and the resolution phase of RA are influenced by 
overweight/obesity status in terms of ST inflammation and bone remodelling. Moreover, the ST histological com-
position found at RA onset strongly supports the lower rate of treatment response, in terms of DAS28 reduction, 
found in obese patients belonging to early RA cohorts37. Therefore, these results suggest that weight control is a 
crucial aim along the whole disease course in RA and interventional studies, including body weight reduction, 
are necessary to definitively confirm the biological effect of adipose tissue on the entity of RA inflammation and 
to envision a personalized approach for obese RA.
Methods
Patients recruitment. One hundred and thirty-eight consecutive patients fulfilling the American College 
of Rheumatology 2010 revised criteria for RA38, were enrolled. RA patients were divided into naïve to treatment 
(n = 70), inadequately responder to Methotrexate (MTX-IR) (n = 43) and patients in stable remission under com-
bination of MTX + TNF-inhibitor (TNF-i) (n = 25). All MTX-IR RA were taking stable dose of MTX (mean 
dose: 13.8 ± 5.7 mg/week). All RA in sustained clinical (DAS44 < 1.6 for at least 6 months) and ultrasound remis-
sion were selected based on the published protocol29. For each enrolled RA, clinical and laboratory evaluations 
included the number of tender and swollen joints on 44, erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP) and Disease Activity Score (DAS). Peripheral blood (PB) samples were tested for IgA and IgM-RF 
(Orgentec Diagnostika, Bouty-UK) and ACPA (Menarini Diagnostics-Italy) using commercial Enzyme-Linked 
Immunosorbent Assay (ELISA) and ChemiLuminescence Immunoassay (CLIA) methods respectively. At study 
entry, for each enrolled RA, Body Mass Index (BMI) was assessed39, and patients were stratified according to the 
following cut-off value references: <25 as normal weight; 25–29.9 as overweight; ≥30 as obese, respectively. After 
study enrolment, all naïve RA started MTX 10 mg/weekly for 2 subsequent administrations and 15 mg/weekly 
afterwards, according to RA management recommendations40. Therefore, each RA was followed every 3 months 
for at least 12 months in an outpatient setting and DAS value was recorded to assess treatment response and the 
BMI category was registered. All methods were carried out in accordance with the declaration of Helsinki. All the 
study experimental protocols were approved by the Ethic Committee of the Università Cattolica del Sacro Cuore 
(Protocol number: 19526/17) and all subjects provided signed informed consent.
Immunohistochemistry for CD68+, CD21+, CD20+ and CD3+ cells in synovial tissue. All enrolled 
RA underwent ultrasound guided ST biopsy of the knee following the published protocol41. Briefly, sections 
were stained for CD68 mouse anti-human monoclonal antibody (514H12) (for macrophages) or CD20, mouse 
anti-human monoclonal antibody (L26) (for B lymphocytes) or CD3 mouse anti-human monoclonal anti-
body (LN10) (for T lymphocytes) or CD21 mouse anti-human monoclonal antibody (2G9) (for follicular den-
dritic cells)42,43 (all by Leica Biosystem, Newcastle-UK) by immunostainer BOND MAX III (Leica). Double 
Immunohistochemical staining for CD21/CD68 and CD20/CD3 was performed as previously described30. Slides 
were examined using a light microscope (Leica DM 2000) and classified as diffuse or follicular based on the immu-
nostaining of CD68, CD21, CD20 and CD3 positive cells42. Specific lymphoid features of the cellular aggregates were 
assessed by staining 3–4 μm-thick FFPE consecutive sections for CD3, CD20 and CD21 as previously defined42,43. 
All tissues were evaluated using a numerical score based on the number of positive cells in the lining and sublining 
areas of the section (three different fields in each section), with a score of 0 indicating no positive cells; 1 indicating 
<10% positive cells; 2 indicating 10–50% positive cells; and 3 indicating >50% positive cells30. Inter-rater agree-
ment coefficients for CD68, CD21, CD20 and CD3 IHC scores were assessed (see Supplementary Table 3).
ELISA assay for IL-6 and IL-1RA plasma levels evaluation. Naive to treatment RA and RA patients 
in stable clinical and ultrasound remission were tested for IL-6 and IL-1RA PB levels using commercial 
Enzyme-Linked ImmunoSorbent Assay (ELISA) kits (all by R&D Systems, United Kingdom). The sensitivity of 
the test was 0.70 pg/ml for IL-6 and 18.3 pg/ml for IL-1RA respectively.
Gene expression profile of synovial tissue of RA patients with naive active disease and in sus-
tained clinical and ultrasound remission based on BMI category. Total RNA was isolated from 
synovial tissue of 15 RA patients (8 from RA with naive active disease and 7 from RA in sustained clinical and 
ultrasound remission as previously described) using the miRneasy kit (Qiagen). RNA was reverse transcribed 
using a cDNA conversion kit (Qiagen). The cDNA was used on the real-time RT2 Profiler PCR Array (QIAGEN, 
Cat. no. PAHS-077Z) in combination with RT2 SYBR® Green qPCR Mastermix (Cat. no. 330529). A set of con-
trols was included on each plate which enabled data analysis using ΔΔCt method of relative quantification, assess-
ment of reverse transcription performance and assessment of PCR performance. The RT² Profiler PCR Array 
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enables SYBR Green-based real-time PCR analysis using Biorad iQ5 real-time PCR system as follows: 95 °C for 
15 min; 40 cycles of 94 °C for 15 s; 55 °C for 30 s; and 70 °C for 30 s. The relative expression was calculated using the 
ΔΔCt method (relative gene expression = 2(ΔCt test − ΔCt control)] and is presented in fold increase relative to 
control. The Web-based GeneGlobe Data Analysis Center was used to analyse the real-time PCR data (Qiagen).
Statistical analysis. Statistical analysis was performed using SPSS V. 20.0 (SPSS. Chicago, Illinois, USA) and 
Prism Software (GraphPad, San Diego, California, USA). Categorical and quantitative variables were described as 
frequencies, percentage and mean ± standard deviation (SD). Data on demographic and clinical features were com-
pared between patients by the non-parametric Mann-Whitney U test or χ2 test, as appropriate. Spearman’s rank cor-
relation test was used for correlation in all analyses. For the gene expression profile, data analysis was performed using 
the supplied software (http://www.qiagen.com/it/shop/genes-and-pathways/data-analysis-center-overview-page/), 
based on Student’s t-test of the replicate 2(−ΔCt) values for each gene in the tested group and in the control group. 
Fold-change values > 1 imply an upregulation while fold-change <1 imply down-regulation. using RT2 Profiler PCR 
array, a t-test was used to identify significant differences in gene expression profiles between overweight/obese and 
normal weight naive active RA, overweight/obese RA in sustained remission and normal weight RA in sustained 
remission used as control. A value of p ≤ 0.05 was considered statistically significant.
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